Good News for Lupin
Lupin Limited's US subsidiary, Lupin Pharmaceuticals, Inc has been able to receive the final authorization for the company's Abbreviated New Drug Application for its lamotrigine tablets, 25 mg, 100 mg, 150 mg and 200 mg strengths, from the US Food and Drug Administration.
Lupin's Lamotrigene is the AB-rated generic correspondent of GlaxoSmithKline's Lamictal tablets that is asserted to be given for the maintenance treatment of bipolar I disorder and is also indicated as adjunctive treatment for definite seizure types.
Lamictal tablets had yearly sales of just about US$ 452 million for the twelve months that ended in March 2010.
New Zealand News
- Tesla to design & build affordable EV in China: Tom Zhu
- First deliveries of all-electric Porsche in Australia to take place this weekend
- Crown Resorts suffers record six-month loss due to COVID-19 closures
- Australia’s Crown Resorts 'not suitable' for Sydney gaming license: Inquiry Commission
- What Does Phasing Out Cheques Tell Us About Finance in New Zealand?